SEC Form 4 · accession 0001209191-15-076831
GYRE THERAPEUTICS, INC. · GYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Augustine Lawlor
Director
Period of report
Oct 22, 2015
Accepted (ET)
Oct 26, 2015 · 7:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001124105
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.40 | Oct 22, 2015 | A | 8,250 | A | — | Oct 22, 2025 | Common Stock | 8,250 | 8,250 | D |
| Stock Option (Right to Buy)F1,F2 | $4.40 | Oct 22, 2015 | A | 6,750 | A | — | Oct 22, 2025 | Common Stock | 6,750 | 6,750 | D |
Explanation of responses
- F1Award vests monthly over three (3) years starting September 1, 2015.
- F2This award is subject to shareholder approval of an amendment to the Issuers' 2015 Stock Incentive Plan.